• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    VivoSim Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    5/6/25 8:05:09 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIVS alert in real time by email
    8-K
    0001497253false00014972532025-04-302025-04-30

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 30, 2025

     

     

    VivoSim Labs, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-35996

    27-1488943

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    11555 Sorrento Valley Rd

    Suite 100

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 224-1000

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value

     

    VIVS

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 8.01 Other Events.

    As previously disclosed by VivoSim Labs, Inc. (the “Company”), on February 19, 2025, the Company received a written notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2024 reported stockholders’ equity of $364,000, and as of February 19, 2025, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations, the Company no longer met the requirement to maintain a minimum of $2,500,000 in stockholders’ equity, as set forth in Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). Prior to that, on January 16, 2025, the Staff had provided a notice to the Company that the Company had not regained compliance with the requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”) and was not eligible for a second 180 calendar day compliance period as the Company did not comply with the requirements for initial listing on the Nasdaq Capital Market. The notice further indicated that, unless the Company timely requested a hearing before a Hearings Panel (the “Hearings Panel”), the Company’s common stock would be subject to delisting. The Company timely requested a hearing before the Hearings Panel and presented its plan for compliance to the Hearings Panel on February 27, 2025. On March 27, 2025, the Hearings Panel granted the Company an exception until April 15, 2025 to demonstrate compliance with Rule 5550(a)(2) and Rule 5550(b)(1).

    On April 30, 2025, the Company received a letter from Nasdaq notifying the Company that it has demonstrated compliance with Rule 5550(a)(2) and Rule 5550(b)(1) as required by the Hearing Panel’s March 27, 2025 decision. The Company will be subject to a Mandatory Panel Monitor for a period of one year from the date of the April 30, 2025 letter pursuant to Nasdaq Listing Rule 5815(d)(4)(B).

    Forward-Looking Statements

    Except for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects or future events, as well as words such as “believes,” “intends,” “expects,” “plans” and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that the Company will continue to maintain compliance with applicable Nasdaq continued listing requirements. Reference is also made to other factors detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K and the Company assumes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this Current Report on Form 8-K, unless required by law.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Number

    Description

    104

              Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    VIVOSIM LABS, INC.

     

     

     

     

    Date:

    May 6, 2025

    By:

    /s/ Keith Murphy

     

     

     

    Name: Keith Murphy
    Title: Executive Chairman

     


    Get the next $VIVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

    SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it will attend the Society of Toxicology ("SOT") meeting in San Diego, CA that takes place March 22-25 and present new data on its NAMkind™ liver and NAMkind™ Intestine model, including data on validating the models for use in predicting toxicity and side effect profiles of antibody drug conjugates (ADCs). Considering the hundreds of ADCs in development across the globe, the potential for off target toxicity due to their common use in oncology to deliver cytotoxic payloads, and a

    2/11/26 8:05:00 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

    SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind™ toxicology services in liver and small intestine. The appointments expand VivoSim's commercial presence across Asia-Pacific, which potentially provides faster access to human-relevant toxicology services for pharmaceutical and biotechnology organizations facing growing pressure to de-risk programs earlier and accelerate timelines. A market inflect

    1/29/26 4:05:00 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

    SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announces it has appointed Amar Sethi, M.D., Ph.D. as its Chief Scientific Officer. Dr. Sethi is a transformational R&D executive with three decades of experience encompassing pharmaceutical drug development, CRO leadership, translational medicine, and diagnostic innovation. He has led global Phase I–IV clinical programs, FDA breakthrough and orphan drug designations, BLA filings, and advance

    1/6/26 8:05:00 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Douglas Jay was granted 15,000 shares, increasing direct ownership by 262% to 20,732 units (SEC Form 4)

    4 - VivoSim Labs, INC. (0001497253) (Issuer)

    1/29/26 7:59:37 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EXECUTIVE CHAIRMAN Murphy Keith was granted 15,000 shares, increasing direct ownership by 136% to 26,053 units (SEC Form 4)

    4 - VivoSim Labs, INC. (0001497253) (Issuer)

    1/29/26 7:59:09 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Milhous Alison Tjosvold was granted 15,000 shares, increasing direct ownership by 306% to 19,899 units (SEC Form 4)

    4 - VivoSim Labs, INC. (0001497253) (Issuer)

    1/29/26 7:51:55 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    SEC Filings

    View All

    SEC Form 10-Q filed by VivoSim Labs Inc.

    10-Q - VivoSim Labs, INC. (0001497253) (Filer)

    2/11/26 4:05:26 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VivoSim Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - VivoSim Labs, INC. (0001497253) (Filer)

    12/18/25 4:05:25 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by VivoSim Labs Inc.

    10-Q - VivoSim Labs, INC. (0001497253) (Filer)

    11/6/25 4:08:13 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    Leadership Updates

    Live Leadership Updates

    View All

    VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

    SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announces it has appointed Amar Sethi, M.D., Ph.D. as its Chief Scientific Officer. Dr. Sethi is a transformational R&D executive with three decades of experience encompassing pharmaceutical drug development, CRO leadership, translational medicine, and diagnostic innovation. He has led global Phase I–IV clinical programs, FDA breakthrough and orphan drug designations, BLA filings, and advance

    1/6/26 8:05:00 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

    SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players

    8/14/25 8:05:12 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care